Processa Pharmaceuticals, Inc. SEC filings PCSA
Processa Pharmaceuticals, Inc. has 705 filings in SEC EDGAR's recent list, going back to Oct 28, 2011. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 23, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| PRER14A | Filing | Aug 8, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2025 | — |
| EFFECT | Filing | Jun 17, 2025 | — |
| CORRESP | Letter to the SEC | Jun 13, 2025 | — |
| CORRESP | Letter to the SEC | Jun 13, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| DRSLTR | Filing | May 1, 2025 | — |
| DRS | Filing | May 1, 2025 | — |
| EFFECT | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2024 | — |
| DEFR14A | Filing | Jun 11, 2024 | — |
| EFFECT | Filing | May 28, 2024 | — |
| CORRESP | Letter to the SEC | May 24, 2024 | — |
| UPLOAD | Letter from the SEC | May 23, 2024 | — |
| EFFECT | Filing | Jan 26, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2024 | — |
| EFFECT | Filing | Jul 9, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2021 | — |
| EFFECT | Filing | Apr 12, 2021 | — |
| CORRESP | Letter to the SEC | Apr 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 5, 2021 | — |
| D | Filing | Feb 19, 2021 | — |
| EFFECT | Filing | Oct 1, 2020 | — |
| CERT | Filing | Oct 1, 2020 | — |
| CORRESP | Letter to the SEC | Sep 29, 2020 | — |
| CORRESP | Letter to the SEC | Sep 29, 2020 | — |
| CORRESP | Letter to the SEC | Sep 25, 2020 | — |
| RW WD | Filing | Sep 25, 2020 | — |
| RW | Filing | Sep 25, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| 8-A12B | Filing | Sep 17, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2019 | — |
| EFFECT | Filing | Nov 9, 2018 | — |
| CORRESP | Letter to the SEC | Nov 7, 2018 | — |
| CORRESP | Letter to the SEC | Oct 30, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2018 | — |
| CORRESP | Letter to the SEC | Oct 9, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2018 | — |
| CORRESP | Letter to the SEC | Sep 14, 2018 | — |
| CORRESP | Letter to the SEC | Sep 14, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2018 | — |
| D | Filing | May 16, 2018 | — |
| NT 10-Q | Filing | May 16, 2018 | Mar 31, 2018 |
| NT 10-K | Filing | Apr 2, 2018 | Dec 31, 2017 |
| D/A | Filing | Dec 27, 2017 | — |
| D | Filing | Dec 5, 2017 | — |
| NT 10-Q | Form 12b-25 | Nov 14, 2017 | Sep 30, 2017 |
| NT 10-K | Form 12b-25 | Mar 31, 2016 | Dec 31, 2015 |
| NT 10-Q | Form 12b-25 | Nov 16, 2015 | Sep 30, 2015 |
| NT 10-Q | Form 12b-25 | Aug 14, 2015 | Jun 30, 2015 |
| NT 10-K | Form 12b-25 | Mar 30, 2015 | Dec 31, 2014 |
| D | Filing | Mar 24, 2015 | — |
| D | Filing | Feb 20, 2015 | — |
| D | Filing | Nov 13, 2014 | — |
| D | Filing | Oct 27, 2014 | — |
| NT 10-Q | Form 12b-25 | Aug 14, 2014 | Jun 30, 2014 |
| D | Filing | Jan 13, 2014 | — |
| D | Filing | Jan 10, 2014 | — |
| D/A | Filing | Sep 30, 2013 | — |
| D | Filing | Jul 12, 2013 | — |
| D | Filing | Jun 24, 2013 | — |
| EFFECT | Filing | Jun 5, 2013 | — |
| CORRESP | Letter to the SEC | May 31, 2013 | — |
| D | Filing | May 28, 2013 | — |
| UPLOAD | Letter from the SEC | May 21, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 25, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2012 | — |
| D | Filing | Aug 10, 2012 | — |
| D | Filing | Oct 28, 2011 | — |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vero Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1533743
- Former names
- Heatwurx, Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.